RECRUITING

Jump: MR Simulation For Radiation Therapy Master Protocol

Talk to us

Conditions

Prostate CancerRecurrent AdenocarcinomaLiver CancerHead and Neck Cancer

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This is a master protocol for a prospective Phase I-II study evaluating feasibility and efficacy of incorporating magnetic resonance imaging (MRI) simulation into the planning of radiation treatments.

Official Title

Judging MR Simulation Procedures: A Phase I-II Study of the Use of Magnetic Resonance Imaging Simulation in the Planning of Radiation Treatments

Quick Facts

Study Start:2020-10-14
Study Completion:2026-10-22
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT04545957

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Participants must have a confirmed malignancy requiring radiation therapy.
  2. * Age: 18 years or older
  3. * ECOG performance status ≤2 (Karnofsky ≥60%, see Appendix A)
  4. * Ability to understand and the willingness to sign a written informed consent document.
  5. * Disease-specific eligibility criteria will be specified in the appropriate subprotocol.
  1. * For MRI involving contrast, history of allergic reactions attributed to gadolinium based IV contrast. Note: If patient will not receive contrast, this is not applicable
  2. * Participants who cannot undergo an MRI
  3. * Disease-specific exclusion criteria will be specified in the appropriate subprotocol

Contacts and Locations

Study Contact

Raymond Mak, MD
CONTACT
617-632-5734
rmak@partners.org

Principal Investigator

Raymond Mak, MD
PRINCIPAL_INVESTIGATOR
Brigham and Women's Hospital

Study Locations (Sites)

Brigham and Women Hospital
Boston, Massachusetts, 02115
United States
Dana Farber Cancer Institute
Boston, Massachusetts, 02215
United States

Collaborators and Investigators

Sponsor: Dana-Farber Cancer Institute

  • Raymond Mak, MD, PRINCIPAL_INVESTIGATOR, Brigham and Women's Hospital

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2020-10-14
Study Completion Date2026-10-22

Study Record Updates

Study Start Date2020-10-14
Study Completion Date2026-10-22

Terms related to this study

Keywords Provided by Researchers

  • Prostate Cancer
  • Recurrent Adenocarcinoma
  • Liver Cancer
  • Head and Neck Cancer

Additional Relevant MeSH Terms

  • Prostate Cancer
  • Recurrent Adenocarcinoma
  • Liver Cancer
  • Head and Neck Cancer